Number of participants experiencing an attacka · people with familial Mediterranean fever
Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).
1 finding from 1 review
Duration of attackse,f · people with familial Mediterranean fever
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
It is very uncertain whether colchicine (oral) changes adverse drug reactions compared with placebo (very low certainty).
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing an attacka · children with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of attacksa · children with familial Mediterranean fever
1 finding from 1 review
Time between attacks · children with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention of AA amyloidosis · children with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · children with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · children with familial Mediterranean fever
1 finding from 1 review
Number of participants experiencing an attacka · people with colchicine‐resistant familial Mediterranean fever
Canakinumab probably leads to lower number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review
Duration of attacks · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time between attacks · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with colchicine‐resistant familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · people with colchicine‐resistant familial Mediterranean fever
1 finding from 1 review